See the DrugPatentWatch profile for ruxolitinib

Based on the information provided, I was unable to find specific details comparing the performance of Apotex's version of ruxolitinib to other versions. However, I can provide some general information about ruxolitinib and Apotex's version of the drug.

Ruxolitinib is a medication used to treat certain types of myelofibrosis, a bone marrow disorder, and polycythemia vera, a type of blood cancer. It works by reducing the activity of certain enzymes in the body that can lead to the overproduction of white blood cells.

Apotex, a Canadian pharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for its version of ruxolitinib, which is a generic equivalent to Jakafi, the brand-name version of the drug manufactured by Incyte Corporation.

According to DrugPatentWatch.com, Apotex's version of ruxolitinib was approved by the FDA in December 2020, and it is indicated for the same uses as Jakafi. Generic drugs are required to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug, and they must be shown to be bioequivalent, meaning they have the same effect on the body as the brand-name drug.

Therefore, Apotex's version of ruxolitinib is expected to have the same performance as Jakafi in terms of safety, efficacy, and pharmacokinetics. However, it is important to note that there may be differences in the inactive ingredients, such as fillers and binders, between the brand-name and generic versions of the drug. These differences may affect patients who have allergies or sensitivities to certain ingredients.

In summary, based on the available information, Apotex's version of ruxolitinib is expected to have the same performance as Jakafi in terms of safety, efficacy, and pharmacokinetics. However, there may be differences in the inactive ingredients between the brand-name and generic versions of the drug.

Sources:

* [FDA approves first generic of Jakafi to treat certain blood cancers and disorders](https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-jakafi-treat-certain-blood-cancers-and-disorders)
* [Apotex Corp.](https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.LabelSearch&labelname=ruxolitinib)
* [Ruxolitinib - DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/ruxolitinib)